tiprankstipranks
The Fly

Prelude Therapeutics sees cash runway into 2Q26

Prelude Therapeutics sees cash runway into 2Q26

Cash, cash equivalents and marketable securities as of December 31, 2024 were $133.6M. The Company anticipates that its existing cash, cash equivalents and marketable securities will fund Prelude’s operations into the second quarter of 2026.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com